September 18th, 2013
Both Overuse and Underuse Explain Disparities in Coronary Revascularization
Larry Husten, PHD
A new study finds that groups who have often been found to receive less medical care — non-whites, women, and people without private insurance or who are from urban and rural areas — are less likely to undergo coronary revascularization. But the same study finds that this disparity may be in no small part due to […]
January 30th, 2013
How Insurance Status Affects Treatment for Patients with CAD
Kim G. Smolderen, PhD, Paul S. Chan, MD, MS and John Ryan, MD
Does a patient’s insurance status affect a physician’s decision to prescribe evidence-based therapies for CAD?
November 15th, 2011
MI FREE: A Free Lunch for Patients and Insurers Alike?
John Ryan, MD
Removing copays increased adherence, decreased events, and saved the sponsoring insurance company a tidy sum. So are the issues with insurance-sponsored studies different from those with pharmaceutical-sponsored ones?
November 14th, 2011
MI FREEE: How Much Do Free Medications Really Cost?
Larry Husten, PHD
Could getting rid of copayments improve adherence to post-discharge medications, leading to better outcomes and reduced costs? That’s the theory tested by the MI FREEE (Post-Myocardial Infarction Free Rx Event and Economic Evaluation) trial, which was presented at the AHA and published simultaneously in the New England Journal of Medicine. Niteesh Choudhry and colleagues randomized 5855 post-MI patients […]
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?